Skip to content
Company Analysis

Evolus, Inc. Common Stock EOLS

A comprehensive view of key metrics, scores, and financial health for Evolus, Inc. Common Stock

Overview of Evolus, Inc.

EOLS NGM
Healthcare Drug Manufacturers - Specialty & Generic Framework: Pharma / Mature Biotech Small Cap
Evolus, Inc. (EOLS), is a Small Cap company, in the Drug Manufacturers - Specialty & Generic industry, last closed at $8.88, about 14.5% overvalued vs fair value, +23.5% 1Y return, ranked 481/1145 in sector.
Metrics Rev Growth 11.6% ROE 587.4% Gross Margin 66.3%
USD 8.88
-4.52%
(Delayed)
• Vol 90d: 60.1%
52-Week Range
Market Cap
$464.61M
Enterprise Value
$584.24M
Overall Score
View breakdown
Overall
Growth
Fair
Profitability
Good
Health
Weak
Efficiency
Fair
Valuation
Fair
Growth
Fair
Profitability
Good
Health
Weak
Efficiency
Fair
Valuation
Fair
Completeness: 94%
Confidence: 57%
Updated: Sep 12
Top Beats

Quick Facts

Website https://www.evolus.com
HQ Newport Beach, CA
Employees 329
Fiscal year Dec 31

Next Events

Earnings Nov 4 Estimated

Fair Value Snapshot

Bear Base Bull
$7
$8
$8
Current: $8.88 -15% vs base

Engine Room Money Flow™

Small Cap

Pharmaceutical / Mature Biotech - Where revenue goes and how value is created

Flow Steps
Total Revenue
$297.2M
11.6%%
Gross Profit
$197.1M
8.1%%
R&D Expense
$9.6M
4.4%%
Operating Income (EBIT)
$-31.3M
-0.8%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Pharmaceutical / Mature Biotech

Quality & Reliability Indicators

R&D Intensity
3.2%
Fair

Lower R&D intensity - may indicate mature portfolio or cost cuts

Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
2
Active Leaks
1/2
Improving
0
High Impact
2
Critical
Locked Leak
Upgrade to view details
Premium
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Evolus, Inc. Common Stock's durable competitive advantages across 6 defense dimensions

Overall Moat Strength
43
/100
Developing
Scores based on quantitative metrics and qualitative factors
Full moat analysis

Key strengths

  • Operating Leverage in Effect Operating leverage is evident (score 0.77), with margins expanding over time.

Key risks

  • ROIC Below WACC or Peers ROIC at 25.5th percentile suggests inefficient capital deployment.
  • Below-Peer Operating Efficiency Operating margin at 34.3th percentile indicates below-peer efficiency.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
43
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Generic Industrial / Default vs Industry Peers 88% Coverage
Trade-Off Triangle Visualization A ternary plot showing EOLS's balance between Growth (41.1%), Profitability (25.5%), and Safety (33.5%). Growth 41% Safety 33% Profitability 25%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

64th percentile vs peers
65
Key Signals
Revenue CAGR 3Y 26.0% 84p Rev Growth YoY 11.6% 70p EPS Growth YoY 1.1% 32p
Strengths
  • Revenue CAGR 3Y in top 20% of peers (26.0%, 84th percentile)
  • D/E Ratio in top 20% of peers (-6.71, 96th percentile)
  • Growth above peer median with strong metric coverage (75%)
  • Debt/FCF Ratio in top 20% of peers (-3.06, 89th percentile)
  • Conservative leverage compared to industry peers
Risks

No significant risks identified for this axis.

Profitability

40th percentile vs peers
40
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

52th percentile vs peers
53
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Evolus, Inc. Common Stock.

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$7.59
- - -
-14.5% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000